Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 4/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.36 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29944991 | 1.00 | SYK (0.52) | SYKERBB2EGFRMRGPRX4RAB9A | |
| SCHEMBL2702047 | 1.00 | SYK (0.52) | SYKERBB2EGFRMRGPRX4RAB9A | |
| SCHEMBL20172279 | 0.82 | MEN1 (0.49) | SYKERBB2EGFRMRGPRX4RAB9A | |
| SCHEMBL30354916 | 0.82 | SYK (0.43) | SYKERBB2EGFRMRGPRX4RAB9A | |
| SCHEMBL30354884 | 0.81 | MAPT (0.53) | SYKRAB9ANPC1CYP19A1CYP11B1 | |
| SCHEMBL5569189 | 0.81 | MAPT (0.53) | SYKRAB9ANPC1CYP19A1CYP11B1 | |
| SCHEMBL29638125 | 0.81 | SYK (0.78) | SYKERBB2EGFRERBB3ERBB4 | |
| SCHEMBL159323 | 0.81 | SYK (0.78) | SYKERBB2EGFRERBB3ERBB4 | |
| SCHEMBL4411432 | 0.80 | MRGPRX4 (0.48) | SYKMRGPRX4NPC1S1PR4CYP3A4 | |
| SCHEMBL21835275 | 0.79 | SYK (0.52) | SYKERBB2EGFRMRGPRX4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | SYK 102/4885ERBB2 1/4885EGFR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.